2014 Indonesian Heart Association Guidelines of Management of Atrial Fibrillation
AbstractAtrial fibrillation is the most frequent arrhythmia in clinical practice and causing huge health problem. Therefore, a national guidelines in management of AF that comprise of pathomechanism, clasifications, anticoagulants management for stroke prevention, rate and rhythm control is developed to ensure patients get best therapeutic option. The guidelines is developed in line with variable health care level in Indonesia from primary up to tertiary care.
2. European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European heart journal 2010;31:2369-429.
3. Wolf PA, Benjamin EJ,Belanger AJ,Kannel WB,Levy D,D:A.gostino RB. Secular trends in the prevalence of atrial fibrillation:The Framingham Study.American heartjournal1996;131:790-5.
4. Setianto B,Malik MS,Supari SF. Studi aritmia pada survei dasar MONICA-Jakarta di Jakarta Selatan. Badan Penelitian dan Pengembangan Kesehatan Depkes Rl 1998.
5. Rl PDdiKK. Gambaran kesehatan usia lanjut di Indonesia.Buletin Jendela Data dan lnformasi Kesehatan 2013:.
6. Wyse DG,Waldo AL, DiMarco JP. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation.The New England journal of medicine 2002;347:1825-33.
7. StewartS,Murphy NF,Walker A,McGuire A,McMurray JJ.Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92.
8. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update ofthe 2010 ESC Guidelines forthe management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace : European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology ofthe European Society of Cardiology 2012;14:1385 -413.
9. lssa ZF. Atrial Fibrillation. In: Miller JM, Zipes DP, eds. Clinical arrhythmology and electrophysiology: a companion to Braunwald’s heart disease. 2nd ed: Saunders;2012.
10. BenoniM, Zimmermann M.Autonomic tone variations before the onset of paroxysmalatrial fibrillation.Circulation 2002;105:2753-9.
11. Po SS,Scherlag BJ,Yamanashi WS,et al. Experimental model for paroxysmal atrial fibrillation arising at the pulmonary vein-atrial junctions. Heart rhythm: the official journal of the Heart Rhythm Society 2006;3:201-8.
12. Daoud EG,Bogun F,Goyal R,et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996;94:1600-6.
13. Fuster V, Ryden LE,Cannom DS,et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHNESC
2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.Journal of the American College of Cardiology 2011;57:e101-98.
14. Moe GK. Rheinboldt WC Abildskov JA.A Computer Model of Atrial Fibrillation. American heart journal1964;67:200-20.
15. Wijffels MC Kirchhof CJ,Dorland R,Allessie MA.Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.Circulation 1995;92:1954-68.
16. Fox CS, Parise H, D’Agostino RB, Sr., et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA : the journal of the American Medical Association 2004;291:2851-5.
17. Kirchhof P, Bax J, Blomstrom-Lundquist C et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF: European heart journal 2009;30:2969-llc.
18. Hodgson-Zingman DM, Karst ML. Zingman LV, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.The New England journalof medicine 2008;359:158-65.
19. Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA: the journal of the American Medical Association 2005;293:447-54.
20. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation.Science 2003;299:251-4.
21. Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke.Nature genetics 2009;41:876-8.
22. Alpert JS,Petersen P, Godtfredsen J. Atrial fibrillation: natural history, complications, and management. Annual review of medicine 1988;39:41-52.
23. Packer DL. Bardy GH,Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction.The American journal of cardiology 1986;57:563-70.
24. Watson T,Shantsila E,Lip GY. Mechanisms ofthrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009;373:155-66.
25. BelletS. Clinical Disorders ofthe Heart Beat.3rd ed.Philadelphia: Lea & Febiger; 1971.
26. European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrilal tion of the European Society of Cardiology (ESC).Europace: European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardia c pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2010;12:1360-420.
27. Fuster V, Ryden LE,Cannom DS,et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report ofthe American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257·354.
28. Levy S, Breithardt G, Campbell RW, et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. European heart journal1998;19:1294·320.
29. Wann LS, Curtis AB, January CT. et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology 2011;57:223·42.
30. Knight BP,Michaud GF, Strickberger SA, Morady F. Electrocardiographic differentiation of atrial flutter from atrial fibrillation by physicians.Journalofelectrocardiology 1999;32:315-9.
31. Defaye P, Dournaux F, Mouton E. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing and clinical electrophysiology: PACE 1998;21:250-5.
32. Atrial Fibrillation (A Fib) Awareness. 2013. at http://www.hrsonline.org/News/AtriaiFibrillation·AFib·Awareness#axzz 2gHiiCTk0.)
33. Page RL Wilkinson WE, Clair WK. McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia.Circulation 1994;89:224-7.
34. Atrial Fibrillation Clinical Presentation. 2013. (Accessed Sep 27, 2013, at http://emedicine. medseape.com/article/151066-clinica1.)
35. Cheng M, Hu Z, LuX,Huang J Gu D. Caffeine intake and atrial fibrillation incidence: Dose response Meta-analysis of prospective cohort studies.Canadian Journalof Cardiology 2014.
36. van den 8os EJ,Constantinescu AA,van Domburg RT. Akin S,Jordaens LJ, Kofflard MJ.Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. European heartjournal2011;32:611-7.
37. Wozakowska-Kaplon B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation.The American journal of cardiology 2004;93:1555-8.
38. Kowey PR, Yannicelli D,Amsterdam E. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting.The American journal of cardiology 2004;94:663 -5.
39. Singer DE,Albers GW,Dalen JE,et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:546S·92S.
40. Wolf PA, Dawber TR,Thomas HE,Jr., Kannel WB.Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.Neurology 1978;28:973-7.
41. Camm AJ,Lip GY, De Caterina R, et al. 2012 focused update ofthe ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation.Developed with the special contribution ofthe European Heart Rhythm Association.European heart journal2012;33:2719-47.
42. Group SRiAFW. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546-54.
43. Hughes M,Lip GY,Guideline Development Group NCGfMoAFiP. Secondary Care NlfH,Clinical E. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors,risk stratification schema and cost effectiveness data.Thrombosis and haemostasis 2008;99:295-304.
44. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.Chest 2010;137:263-72.
45. Banerjee A,Taillandier S, Olesen JB, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the LoireValley AtrialFibrillation Project.European journal of heart failure 2012;14:295-301.
46. Friberg L Rosenqvist M,Lip GY.Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. European heart journal2012;33:1500-l0.
47. Friberg L Benson L Rosenqvist M, Lip GY.Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. Bmj 2012;344:e3522.
48. Olesen JB, Fauchier L Lane DA, Taillandier S, Lip GY. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.Chest 2012;141:147-53.
49. Boriani G,Botto GL Padeletti Let al. Improving stroke risk stratification using the CHADS2 and CHA2DS2 VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke;a journal of cerebral circulation 2011;42:1768-70.
50. Olesen JB,Torp-Pedersen C Hansen ML Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thrombosis and haemostasis 2012;107:1172-9.
51. Olesen JB,Lip GY,Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Bmj 2011;342:dl24.
52. Chao TF,Lin YJ. Tsao HM, et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. Journal of the American College of Cardiology 2011;58:2380-5.
53. Pisters R,Lane DA,Nieuwla at R,de Vos CR Crijns HJ, Lip GY. A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.Chest 2010;138:1093-100.
54. Gallego P. Roldan V,Torregrosa JM, et al. Relation ofthe HAS-BLED bleeding risk score to major bleeding,cardiovascular events,and mortality in anticoagulated patients with atrial fibrillation.Circulation Arrhythmia and electrophysiology 2012;5:312·8.
55. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Archives of internal medicine 1994;154:1449-57.
56. De Caterina R, Husted S,Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.Journal of the American College of Cardiology 2012;59:1413-2S.
57. Morgan CL, McEwan P,TukiendorfA,Robinson PA, Clemens A,PlumbJM.Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thrombosis research 2009;124:37·41.
58. Suriapranata IM,Tjong WY,Wang T, et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.BMC medical genetics 2011;12:80.
59. Connolly SJ, Ezekowitz MD,YusufS,et al. Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine 2009;361:1139-51.
60. Ezekowitz MD,Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J,Aikens TH,Yang S, Reilly PA, Lip GY, Yusuf S. Dabigatran and warfarin in vitamin K antagonist-naïve and experienced cohorts with atrial fibrillation.Circulation.2010;122(22):2246-2253.
61. Patel MR,Mahaffey KW,Garg J, PanG,Singer DE,Hacke W,Breithardt G,Halperin JL, Hankey GJ,Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD,Fox KA,Califf RM.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N EngIJ Med. 2011;365(10):883-891.
62. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH,Diaz R,Talajic M,Zhu J,Pais P, Budaj A,Parkhomenko A,Jansky P,Commerford P, Tan RS, Sim KH, Lewis BS,Van Mieghem W,Lip GY, Kim JH, Lanas·Zanetti F, GonzalezHermosillo A,Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R,Yusuf S. Apixaban in patients with atrial fibrillation.N EngIJ Me d.2011;364(9):806-817.
63. Granger CB,Aiexander JH,McMurray JJ,Lopes RD,Hylek EM, HannaM,AI·Khalidi HR,Ansell J,Atar D,Avezum A, Bahit MC Diaz R,Easton JD,Ezekowitz JA, Flaker G,Garcia D,Geraldes M, Gersh BJ,Golitsyn S,Goto S,Hermosillo AG,Hohnloser SH,Horowitz J,Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J,Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation.N EngIJ Med.2011;365(11):981·992.
64. Bayard YL, Omran H, Neuzil P, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. Eurolntervention: journal of EuroPCR in collaboration with the Working Group on lnterventional Cardiology of the European Society of Cardiology 2010;6:220-6.
65. ParkJW,Bethencourt A, Sievert H,et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2011;77:700-6.
66. Holmes DR,ReddyVY,Turi ZG,et al. Percutaneous closure ofthe left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42.
67. ReddyVY, Holmes D,Doshi SK, Neuzil P, Kar S.Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011 ;123:417-24.
68. Lip GY,Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.Journal of the American College of Cardiology 2012;60:738-46.
69. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.Annals of internal medicine 2011 ;154:1-11.
70. Shah SV,Gage BF. Cost-effectiveness ofdabigatran for stroke prophylaxis in atrial fibrillation.Circulation 2011 ;123:2562-70.
71. Banerjee A Lane DA Torp-Pedersen C. Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thrombosis and haemostasis 2012;1 07:584-9.
72 Skanes A(.Healey JS,CairnsJA,et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines:recommendations for stroke prevention and rate/ rhythm control. The Canadian journal of cardiology. 2012;28(2):125-136.
73. Barrett YC Wang Z, Frost C. Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thrombosis and haemostasis 201 0;1 04:1263-71.
74. Pengo V,Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation ofThrombosis Centers (FCSA).Thrombosis and haemostasis 2011 ;1 06:868-76.
75. Huisman MV, Lip GY,Diener HC Brueckmann M,van Ryn J,Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.Thrombosis and haemostasis 2012;1 07:838-47.
76. Sie P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Archives of cardiovascular diseases 2011 ;1 04:669-76.
77. Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNKOnline bRiDging REgistRy (BORDER).Thrombosis and haemostasis 2012;1 08:65-73.
78. Nagarakanti R,Ezekowitz MD, Oldgren J,et al. Dabigatran versus warfarin in patients with atrial fibrillation:an analysis of patients undergoing cardioversion.Circulation 2011;123:131-6.
79. Lakkireddy D,ReddyYM,DiBiase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.Journal of the American College of Cardiology 2012;59:1168-74.
80. Carlos Brotons JC Gregory Lip, Kathryn Taubert. Atrial fibrillation in primary care: bringing atrial fibrillation practice closer to guidelines. In: International Atrial Fibrillation Association SAfE,World Heart Federation ed.2012.
81. Pool PE, Herron JM, Rosenblatt S, et al. Sustained release diltiazem: duration of antihypertensive effect.Journal of clinical pharmacology 1989;29:533-7.
82. de Muinck E,Wagner G,vd Ven LL, Lie Kl.Comparison of the effects oftwo doses ofbisoprolol on exercise tolerance in exercise induced stable angina pectoris. European heart journal 1987;8 Suppl M:315.
83. Stout SM, Nielsen J,Welage LS, et al. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.Journal of clinical pharmacology 2011;51:389 96.
84. Gillis AM,Verma A,Talajic M,Nattel S,Dorian P,Committee CCSAFG.Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. The Canadian journal of cardiology 2011;27:47-59.
85. Practical Rate and Rhythm Management of Atrial Fibrillation: Heart Rhythm Society;2010.
86. Boos CJ, Carlsson J, More RS.Rate or rhythm control in persistent atrial fibrillation? QJM: monthly journal ofthe Association of Physicians 2003;96:881-92.
87. Van Gelder IC Groenveld HF,Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation.The New England journal of medicine 2010;362:1363-73.
88. Suttorp MJ,Kingma JH, Jessurun ER,Lie AHL, van Hemel NM,Lie Kl. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.Journal of the American College of Cardiology 1990;16:17227.
89. Dalzell GW,Anderson J,Adgey AA.Factors determining success and energy requirements for cardioversion of atrial fibrillation.The Quarterly journal of medicine 1990;76:90313.
90. Lundstrom T, Ryden L. Chronic atrial fibrillation. Longterm results of direct current conversion.Acta medica Scandinavica 1988;223:53-9.
91. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. The New England journal of medicine 2000;342:91320.
92. Hylek EM, Skates SJ, Sheehan MA, Singer DE.An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.The New England journal of medicine 1996;335:5406.
93. Frick M,Frykman V,Jensen Urstad M,Ostergren J, Rosenqvist M. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation.Clinical cardiology 2001;24:23844.
94. Hsu LF, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure.The New England journal of medicine 2004;351:2373-83.
95. Yuniadi Y,Moqaddas H, Hanafy DA,Munawar M. Atrial fibrillation ablation guided with electroanatomical mapping system: A one year follow up.Med J lndones 2010;19:172-8.
96. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. The New England journal of medicine 1998;339:659·66.
97. Martin DO,Saliba W,McCarthy PM,et al. Approaches to restoring and maintaining normal sinus rhythm.Cleveland Clinic journal of medicine 2003;70 Suppi3:S12·29.
98. Aizer A,Gaziano JM,Cook NR,Manson JE,Buring JE,Albert CM. Relation of vigorous exercise to risk of atrial fibrillation.The American journal of cardiology 2009;103:1572·7.
99. Mozaffarian D,Furberg CD,Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults:the cardiovascular health study. Circulation 2008;118:800·7.
100. HeidbuchelH,Panhuyzen· Goedkoop N,Corrado D,etaI. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part 1: Supraventricular arrhythmias and pacemakers. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology,Working Groups on Epidemiology&Prevention and Cardiac Rehabilitation and Exercise Physiology 2006;13:475·84.
101. Vahanian A, Baumgartner H,BaxJ,et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.European heartjournal2007;28:230·68.
102. Hu CL, Jiang H,Tang QZ, et al. Comparison of rate control and rhythm control in patients with atrial fibrillation after percutaneous mitralballoon valvotomy: a randomised controlled study. Heart 2006;92:1096·101.
103. Schmitt J,Duray G,Gersh BJ,Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence,clinical features and prognostic implications.European heartjournal2009;30:1038-45.
104. Lip GY,Huber K,Andreotti F,et al.Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.Thrombosis and haemostasis 2010;103:13-28.
105. Fitzmaurice DA,Hobbs FD,Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. Bmj 2007;335:383.
106. Wyse DG. Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing 2009;25:25·9.
107. Hohnloser SH,Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelettherapy: an ACTIVEW Substudy.Journal of the American College of Cardiology 2007;50:2156-61.
108. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators.Journal ofthe American College of Cardiology 2000;35:183-7.
109. Goette A,Bukowska A,Dobrev D, et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. European heart journal 2009;30:1411-20.
110. Pieper PG,Balci A,Van DijkAP.Pregnancy in women with prosthetic heart valves.Netherlands heart journal: monthly journalofthe Netherlands Society of Cardiology and the Netherlands Heart Foundation 2008;16:406-11.
111. Crystal E,Garfinkle MS,Connolly SS,Ginger IT,SleikK,YusufSS.Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. The Cochrane database of systematic reviews 2004:CD003611.
112. Burgess DC Kilborn MJ, Keech AC. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. European heart journal2006;27:2846-57.
113. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery.JAMA:the journal of the American Medical Association 2004;291:1720-9.
114. Sawin CT,Geller A, Wolf PA,et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.N EngI J Med 1994;331:1249-52.
115. Eldar M,CanettiM,Rotstein Z,et al. Significance of paroxysmalatrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups.Circulation 1998;97:965-70.
116. Le Heuzey JY,De Ferrari GM,Radzik D,SantiniM,Zhu J, Davy JM.A short-term,randomized, double-blind,para !lei-group study to evaluate the efficacy and safety of droneda rone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of cardiovascular electrophysiology 2010;21:597-605.
117. Munger TM, Packer DL, Hammill SC, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 1993;87:866-73.
118. Leitch JW, Klein GJ,Yee R,Murdock C. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern.Circulation 1990;82:1718-23.
119. Klein GJ, Bashore TM,Sellers TD, Pritchett EL, Smith WM,Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N EngIJ Med 1979;301:1080-5.
120. ZardiniM,Yee R,Thakur RK. Klein GJ.Risk of sudden arrhythmic death in the Wolff-Parkinson-White syndrome: current perspectives. Pacing Clin Electrophysiol1994;17:966-75.
121. Blomstrom-Lundqvist C. Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmai s).Circulation 2003;108:1871-909.
122. Han ZH, Li Y, Jiang TY, Wu XS, Gao YC, Chen F. [The incidence and predictor s of atrial fibrillation in hypertrophic cardiomyopathy]. Zhonghua nei ke za zhi [Chinese journal of internal medicine] 2008;47:475-7.
123. Kappenberger L, Linde(.DaubertC,et al.Pa cing in hypertrophic obstructive cardiomyopathy. A randomized crossover study.PIC Study Group. Eur Heart J 1997;18:1249-56.
PDF downloads: 2951
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).